Recruiting Pulmonary Embolism Studies in London
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on stand...
About Pulmonary Embolism Clinical Trials in London
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 2 pulmonary embolism clinical trials recruiting participants in London, ONTARIO. These studies are seeking a combined 166 participants. Research is being sponsored by Crinetics Pharmaceuticals Inc., Hanmi Pharmaceutical Company Limited. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in London — FAQ
Are there pulmonary embolism clinical trials in London?
Yes, there are 2 pulmonary embolism clinical trials currently recruiting in London, ONTARIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in London?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the London research site will contact you about next steps.
Are clinical trials in London free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many London studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 2 active trials in London are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov